Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Stryker (SYK)

NYSE: SYK · Medical Devices · Portage, MI

Our rating: Positive

Positive reaffirmed at $306.81, moderate conviction, November 2, 2026.

Breaks if: The Positive call is wrong if reported revenue growth falls below 7% for two consecutive quarters within the next four reported periods — roughly halving the current pace — or if trailing twelve-month free cash flow drops below $3.5 billion, signaling that the cash-conversion quality we are relying on is narrowing. Either condition would undercut the growth premium embedded in a 36.5x P/E. The call would step toward Conviction if net margin demonstrates a clear trend toward 15% across two straight quarters while top-line growth holds above 9%.

Key figures

Market value$118.0B
Revenue, last 12 months$26.3B
Net income, last 12 months$3.6B
Free cash flow, last 12 months$4.6B
Price to earnings32.6×
Free cash flow yield3.9%
Dividend yield1.1%
Operating margin20.7%
Return on equity16.0%
Beta to the S&P 5000.54
Volatility, annualized26.2%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$6.5B7.6%$1.96$1.2B
June 30, 2026$6.6B9.4%$3.30$1.1B
March 31, 2026$6.0B2.6%$1.93$415M
December 31, 2025$7.2B11.4%$2.20$1.9B
September 30, 2025$6.1B10.2%$2.22$1.4B
June 30, 2025$6.0B11.1%$2.29$928M
March 31, 2025$5.9B11.9%$1.69$127M
December 31, 2024$6.4B10.7%$1.41$1.7B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

22 ledger entries and 42 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.